A track record of
In funding more than $200 million in CF research since 1960, we’ve had a hand in nearly every major CF discovery. It was Canadian researchers who:
Discovered the gene responsible for CF, opening the door to targeting the cause of the disease rather than its symptoms.
Developed and demonstrated the clinical benefits of the revolutionary high-fat diet adopted globally to improve nutrition.
Purified the CFTR protein, improving understanding of its structure and function, and leading to development of KALYDECO™.
Developed the “Toronto Protocol” that has now been broadly adopted to repair donor lungs and improve transplant outcomes.
Identified a novel approach to treating bacterial infections that was adopted as a best practice in clinical care.
In funding more than $200 million in CF research since 1960, we’ve had a hand in nearly every major CF discovery. It was Canadian researchers who:
Discovered the gene responsible for CF, opening the door to targeting the cause of the disease rather than its symptoms.
Developed and demonstrated the clinical benefits of the revolutionary high-fat diet adopted globally to improve nutrition.
Purified the CFTR protein, improving understanding of its structure and function, and leading to development of KALYDECO™.
Developed the “Toronto Protocol” that has now been broadly adopted to repair donor lungs and improve transplant outcomes.
Identified a novel approach to treating bacterial infections that was adopted as a best practice in clinical care.
Canadians with CF are living significantly longer than they were in the 1970s when the median age of survival was 25.
Now it’s more than double that.
Let’s go even further to reduce the treatment burden, improve quality of life and ensure no one with CF gets left behind.
Dr. Christine Bear is looking for evidence that Trikafta can improve lung health for those who have been denied access due to their rare mutations.
A McGill University research team led by Dr. Dao Nguyen is tackling the problem of bacterial infections in the lungs of people with CF.
Amid the challenges of the pandemic came an opportunity to give the CF community a stronger voice in the research we fund.
COMMUNITY STORIES
"All we want is for Sebastian to have a full, long, adventurous life that he deserves. This disease is still a ticking clock for us and others.”
"…It was like a punch in the gut to learn [this new treatment] wouldn't help any of my children. Now I'm worried my kids will be left behind."
“We strongly believe our time will come for a ‘miracle’ drug, and that’s because one thing has kept us going all these years: Hope.”
COMMUNITY STORIES
“All we want is for Sebastian to have a full, long, adventurous life that he deserves. This disease is still a ticking clock for us and others.”
“…It was like a punch in the gut to learn [this new treatment] wouldn't help any of my children. Now I'm worried my kids will be left behind."
“We strongly believe our time will come for a ‘miracle’ drug, and that’s because one thing has kept us going all these years: Hope.”
This focused approach from CF Canada will be invaluable to the CF research community and will help us bring about innovative new therapies.
Dr. Christine Bear, Cystic Fibrosis Canada funded Researcher,
for research advances that will drive improvements in treatment and care for all with CF.
1305-20 Eglinton Avenue West
Toronto, Ontario, M4R 1K8
1-800-378-2233
[email protected]
1-800-378-2233
© 2025 Cystic Fibrosis Canada. All Rights Reserved
Charitable Registration No. 10684-5100 RR0001